ArticleJournal for immunotherapy of cancer2019
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 71 citations in OpenAlex.
- Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.Frontiers in immunology · 2024Trial
- Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.Nature communications · 2023Trial
- Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.Frontiers in immunology · 2021Trial
- Shaping Antitumor Immunity with Peptide Vaccines: Implications of Immune Modulation at the Vaccine Site.Vaccines · 2025Review
- Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.Acta pharmaceutica Sinica. B · 2025Review
- Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case.Journal for immunotherapy of cancer · 2025Article
- Recent developments in peptide vaccines against Glioblastoma, a review and update.Molecular brain · 2025Review
- PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development.Journal for immunotherapy of cancer · 2025Article
- TLR agonists as adjuvants for viral vaccines: mechanisms, applications, and future directions.Frontiers in microbiology · 2025Review
- Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.Frontiers in immunology · 2025Article
- Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.Acta pharmaceutica Sinica. B · 2024Review
- An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer.Vaccines · 2024Article
- Nano-carrier DMSN for effective multi-antigen vaccination against SARS-CoV-2.Journal of nanobiotechnology · 2024Article
- Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens.Exploration of drug science · 2024Article
- AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.Frontiers in oncology · 2024Article
- Article
- iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.Frontiers in oncology · 2024Article
- Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.Blood cancer discovery · 2023Article
- Trial watch: Toll-like receptor ligands in cancer therapy.Oncoimmunology · 2023Article
- Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
37 authors at 9 institutions in 4 countries.
Hans-Georg RammenseeDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany. rammensee@uni-tuebingen.de.
Karl-Heinz WiesmüllerEMC microcollections GmbH, Tübingen, Germany.
P Anoop ChandranDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Henning ZelbaDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Elisa RuschDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Cécile GouttefangeasDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Daniel J KowalewskiDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Moreno Di MarcoDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Sebastian P HaenDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Juliane S WalzDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Yamel Cardona GloriaDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Johanna BödderDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Jill-Marie SchertelFaculty of Medicine Carl Gustav Carus, Institute of Immunology, Technische Universität Dresden, Dresden, Germany.
Antje TungerFaculty of Medicine Carl Gustav Carus, Institute of Immunology, Technische Universität Dresden, Dresden, Germany.
Luise MüllerFaculty of Medicine Carl Gustav Carus, Institute of Immunology, Technische Universität Dresden, Dresden, Germany.
Maximilian KießlerFaculty of Medicine Carl Gustav Carus, Institute of Immunology, Technische Universität Dresden, Dresden, Germany.
Rebekka WehnerFaculty of Medicine Carl Gustav Carus, Institute of Immunology, Technische Universität Dresden, Dresden, Germany.
Marc SchmitzFaculty of Medicine Carl Gustav Carus, Institute of Immunology, Technische Universität Dresden, Dresden, Germany.
Meike JakobiNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Nicole Schneiderhan-MarraNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Reinhild KleinDepartment of Oncology, Hematology, Immunology, Rheumatology and Pulmonology, University Hospital of Tübingen, Tübingen, Germany.
Karoline LaskeDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Kerstin ArtznerDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Linus BackertDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Heiko SchusterDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Johannes SchwenckCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tubingen, Germany.
Alexander N R WeberDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Bernd J PichlerCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tubingen, Germany.
Manfred KneillingCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tubingen, Germany.
Christian la FougèreGerman Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tübingen, Tübingen, Germany.
Stephan ForchhammerDepartment of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
Gisela MetzlerDepartment of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
Jürgen BauerDepartment of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
Benjamin WeideDepartment of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
Wilfried SchippertDepartment of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
Stefan StevanovićDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.
Markus W LöfflerDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany. markus.loeffler@med.uni-tuebingen.de.ORCID 0000-0003-2513-1317
German Cancer Research Center · DEInstitut de Biologie Moléculaire et Cellulaire · FRUniversity Children's Hospital Tübingen · DEImmatics Biotechnologies (Germany) · DEInstitute of Immunology · HRSiemens (Germany) · DENatural and Medical Sciences Institute · DEEMC Microcollections (Germany) · DEResearch Institute for Work, Technology and Culture · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe previously showed that the bacterial lipopeptide Pam CASE PRESENTATION: We now designed a new water-soluble synthetic Pam
conclusionThus, in one volunteer we show a granuloma forming by peptides combined with an efficient adjuvant in a water-in-oil-emulsion, inducing antigen specific T cells detectable in circulation and at the vaccination site, after one single vaccination only. The ex vivo T cell responses in peripheral blood were detectable for more than one year and could be strongly boosted by a second vaccination. Hence, XS15 is a promising adjuvant candidate for peptide vaccination, in particular for tumor peptide vaccines in a personalized setting.
Indexed as
Adjuvants, ImmunologicB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDendritic CellsGranulomaHealthy VolunteersHEK293 CellsHumansKiller Cells, NaturalLigandsMaleMiddle AgedPeptidesToll-Like Receptor 1Toll-Like Receptor 2Adjuvants, ImmunologicLigandsPeptidesToll-Like Receptor 1Toll-Like Receptor 2AdjuvantImmunotherapyLipopeptideTLR1/2 ligandVaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.